Formycon: FYB206’s reference drug is oncology blockbuster Keytruda – PT up, BUY
Formycon has revealed the reference drug for its biosimilar candidate FYB206, Keytruda, the #1 immuno-oncology drug by Merck Co.
Formycon: FYB206’s reference drug is oncology blockbuster Keytruda – PT up, BUY
Formycon has revealed the reference drug for its biosimilar candidate FYB206, Keytruda, the #1 immuno-oncology drug by Merck Co.